

04<sup>th</sup> November 2025

To

The BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai – 400001  
**Scrip Code: 517556**

National Stock Exchange of India Limited  
“Exchange Plaza, Bandra Kurla Complex,  
Bandra (E)  
Mumbai - 400051  
**Symbol: PVP**  
**Debt-18PVL29A, 18PVL29**

Dear Sir/Madam,

**Subject: Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 – Completion of Acquisition of Stake in 7 Med India Private Limited (“7Med”)**

In continuation to our earlier intimation dated 28<sup>th</sup> August 2025, wherein the Company had informed about its proposed acquisition of an equity stake in 7 Med, we wish to inform that the first phase of the transaction has been successfully completed today in accordance with the terms and conditions of the Share Purchase and Shareholders’ Agreement executed between the parties.

Pursuant to the completion of the first phase, PVP Ventures Limited now holds 14,939 equity shares, representing 33.24% of the total paid-up share capital of 7 Med. This acquisition forms part of the Company’s broader strategic initiative to diversify and strengthen its presence in the healthcare sector. The transaction envisages PVP Ventures Limited acquiring 50.62% within a period of twelve months from 28<sup>th</sup> August 2025.

The brief details, as required under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in accordance with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/CIR/P/2023/123 dated 13<sup>th</sup> July 2023, are enclosed herewith as Annexure A.

We request you to kindly take the same on record.

This is for your information and records.

Kindly take the above information on records.

**For PVP Ventures Limited**

PRASAD VEERA  
POTLURI

Digitally signed by PRASAD VEERA POTLURI  
DN: cn=PRASAD VEERA POTLURI, o=PVP Ventures Limited  
Reason: I am the author of this document  
Location:  
Date: 2025.11.04 18:43:05.30

**Prasad V Potluri**  
**Chairman & Managing Director**

**Attached: As in above**

**Annexure-I**

**Details required to be provided while disclosing event under Regulation 30 Para A of Schedule III of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/0155 dated 11<sup>th</sup> November 2024:**

S.NO	PARTICULARS	DETAILS
1	Name of the target entity, details in brief such as size, turnover etc.;	7Med India Pvt. Ltd.
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	The investment does not fall within the ambit of Related Party Transactions and the promoters/ promoter group/ group companies of the Company do not have any existing interest either directly/indirectly in the entity being acquired.
3	Industry to which the entity being acquired belongs;	Healthcare
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Expansion into the healthcare sector.
5	Brief details of any governmental or regulatory approvals required for the acquisition;	Nil
6	Indicative time period for completion of the acquisition;	<p>The Company has entered into a binding agreement to acquire an initial 33.24% equity stake in 7 Med, and the said acquisition has been completed today.</p> <p>Further, the Company is contractually obligated to acquire an additional 4,263 shares, translating to a 41.23% stake, over the next few months.</p> <p>As per the executed contract, the Company will further increase its</p>

		shareholding to 50.62% within twelve months from 28 <sup>th</sup> August 2025.
7	Consideration -whether cash consideration or share swap or any other form and details of the same;	Cash consideration.
8	Cost of acquisition and/or the price at which the shares are acquired	The transaction shall be a combination of both primary and secondary stake purchase amounting to an outlay of circa INR 127 crores for this majority shareholding (50.62%).
9	Percentage of shareholding / control acquired and / or number of shares acquired	As mentioned in the point no 6.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	7Med India Pvt Ltd is among the top five organized players in India's renal care sector, offering a comprehensive range of dialysis services across its pan-India network. The target company has reported an EBITDA of approximately INR 10 crore for the current financial year.

**For PVP Ventures Limited**

PRASAD VEERA  
POTLURI

Digitally signed by PRASAD VEERA POTLURI  
DN: cn=PRASAD VEERA POTLURI c=IN  
o=Personal  
Reason: I am the author of this document  
Location:  
Date: 2025-11-04 18:44:05:30

**Prasad V Potluri**  
**Chairman & Managing Director**